Radiolabeled Nanocarriers as Theranostics—Advancement from Peptides to Nanocarriers

Desai, Prachi; Rimal, Rahul; Sahnoun, Sabri E. M.; Mottaghy, Felix M.; Möller, Martin; Morgenroth, Agnieszka; Singh, Smriti

doi:10.1002/smll.202200673

Cited by 21 publications

(13 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New biomaterials, such as nanoparticles, dendrimers, micelles, liposomes, and nanogels, including nanomedicine, , which could offer more precise pharmacotherapy options with improved safety profiles, especially in cisplatin and antibiotics, could attenuate nephrotoxicity ( Cooper et al, 2014 ; Desai et al, 2022 ). Reports showed that cisplatin conjugated to a polyphosphazene, lipid-coated cisplatin nanoparticle, and cholesterol-tethered platinum II-based nanoparticle could increase the antitumor effect and reduce nephrotoxicity ( Sengupta et al, 2012 ; Guo et al, 2013 ; Patil et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Bibliometric and visual analysis of nephrotoxicity research worldwide

Duan

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Nephrotoxicity of drugs contributes to acute kidney injury with high mortality and morbidity, which crucially limits the application and development of drugs. Although many publications on nephrotoxicity have been conducted globally, there needs to be a scientometric study to systematically analyze the intellectual landscape and frontiers research trends in the future.Methods: Publications on nephrotoxicity from 2011 to 2021 were collected to perform bibliometric visualization using VOSviewer, CiteSpace, and Scimago Graphica software based on the Web of Science Core Collection.Results: A total of 9,342 documents were analyzed, which were primarily published in the United States (1,861), China (1,724), and Egypt (701). For institutions, King Saud University (166) had the most publications; Food and Chemical Toxicology, PLOS One, and Antimicrobial Agents and Chemotherapy were productive journals, primarily concentrating on the mechanisms of nephrotoxicity and renoprotective in cisplatin and antibiotics, especially in oxidative stress. Burst detection suggested that cisplatin, piperacillin-tazobactam, vancomycin-induced nephrotoxicity, antioxidants, and new biomaterials are frontiers of research.Conclusion: This study first provides an updated perspective on nephrotoxicity and renoprotective strategies and mechanisms. This perspective may benefit researchers in choosing suitable journals and collaborators and assisting them in the deep understanding of the nephrotoxicity and renoprotective hotspots and frontiers.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometric and visual analysis of nephrotoxicity research worldwide

Duan

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Radiopharmaceuticals are one of the most important tools for fighting cancer, and the development of peptide receptor radionuclide therapy (PRRT) depends on the knowledge gathered from radiotherapy [ 90 ]. The mechanistic pathways of radiopharmaceuticals show that some important parameters need to be addressed, such as the complete measurement of physiological and biological functions at the targeted sites ( Figure 2 ) [ 48 ]. PRRT solely depends on the process of amassing radiopharmaceuticals at the definite site, which is regulated by several biological processes such as the transference of biochemical species and enzymatic exchanges.…”

Section: Radiopharmaceuticals With Radiolabelled Peptides Towards Can...mentioning

confidence: 99%

“…β-emitters cause repairable damage to single-strand DNA. Reproduced with permission, copyright JOHN WILLEY AND SONS [ 48 ].…”

Section: Figures Scheme and Tablementioning

confidence: 99%

See 1 more Smart Citation

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics

Chakraborty

Mondal

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Radiopharmaceutical therapy, which can detect and treat tumours simultaneously, was introduced more than 80 years ago, and it has changed medical strategies with respect to cancer. Many radioactive radionuclides have been developed, and functional, molecularly modified radiolabelled peptides have been used to produce biomolecules and therapeutics that are vastly utilised in the field of radio medicine. Since the 1990s, they have smoothly transitioned into clinical application, and as of today, a wide variety of radiolabelled radionuclide derivatives have been examined and evaluated in various studies. Advanced technologies, such as conjugation of functional peptides or incorporation of radionuclides into chelating ligands, have been developed for advanced radiopharmaceutical cancer therapy. New radiolabelled conjugates for targeted radiotherapy have been designed to deliver radiation directly to cancer cells with improved specificity and minimal damage to the surrounding normal tissue. The development of new theragnostic radionuclides, which can be used for both imaging and therapy purposes, allows for more precise targeting and monitoring of the treatment response. The increased use of peptide receptor radionuclide therapy (PRRT) is also important in the targeting of specific receptors which are overexpressed in cancer cells. In this review, we provide insights into the development of radionuclides and functional radiolabelled peptides, give a brief background, and describe their transition into clinical application.

show abstract

“…Delivering therapeutic radionuclides into tumors is a promising strategy to enhance the effect of radiation on tumors and decrease radio-toxicity to neighboring normal tissues [ 33 ]. Generally, therapeutic radionuclides (such as 131 I and 90 Y [ 47 ]) are specifically delivered into tumors via suitable tumor-homing carriers, chiefly liposomes, microparticles, nanoparticles, micelles, dendrimers, and hydrogels [ 33 , 48 ]. Here, we describe the utilization of microparticles and nanoparticles in delivering therapeutic radionuclides.…”

Section: Chromatographic Matrices and Corresponding Applications In R...mentioning

confidence: 99%

Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy

Xue

Fan

2022

Biomolecules

View full text Add to dashboard Cite

Antibodies have become an important class of biological products in cancer treatments such as radiotherapy. The growing therapeutic applications have driven a demand for high-purity antibodies. Affinity chromatography with a high affinity and specificity has always been utilized to separate antibodies from complex mixtures. Quality chromatographic components (matrices and affinity ligands) have either been found or generated to increase the purity and yield of antibodies. More importantly, some matrices (mainly particles) and affinity ligands (including design protocols) for antibody purification can act as radiosensitizers or carriers for therapeutic radionuclides (or for radiosensitizers) either directly or indirectly to improve the therapeutic efficiency of radiotherapy. This paper provides a brief overview on the matrices and ligands used in affinity chromatography that are involved in antibody purification and emphasizes their applications in radiotherapy to enrich potential approaches for improving the efficacy of radiotherapy.

show abstract

Radiolabeled Nanocarriers as Theranostics—Advancement from Peptides to Nanocarriers

Cited by 21 publications

References 130 publications

Bibliometric and visual analysis of nephrotoxicity research worldwide

Bibliometric and visual analysis of nephrotoxicity research worldwide

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics

Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy

Contact Info

Product

Resources

About